Overall, these findings underscore the importance of glycosylation in regulating PD-L2's stability and function, offering new avenues for therapeutic interventions aimed at modulating PD-L2's interactions with PD-1 to improve cancer immunotherapy outcomes. The gene discussed is PDCD1LG2; the disease is cancer.